Imperial College London
Alternate

Dr. Ramzi Y Khamis MB ChB PhD FESC FRCP

Faculty of Medicine, National Heart & Lung Institute

Reader in Cardiology
 
 
 
//

Contact

 

+44 (0)20 7594 6842r.khamis

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Khan:2021:10.3390/antiox10010132,
author = {Khan, TZ and Haskard, D and Hartley, A and Caga-Annan, M and Pennell, DJ and Collins, P and Barbir, M and Khamis, R},
doi = {10.3390/antiox10010132},
journal = {Antioxidants},
title = {Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)},
url = {http://dx.doi.org/10.3390/antiox10010132},
volume = {10},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Aims: An abundance of epidemiological evidence demonstrates that elevated lipoprotein(a) (Lp(a)) represents a significant contributing risk factor towards the development of cardiovascular disease. In particular, raised Lp(a) may play a mechanistic role in patients with refractory angina. Studies have also shown a correlation between oxidised LDL (oxLDL) levels and atherosclerotic burden as well as rates of cardiovascular events. Antibodies against oxLDL (anti-oxLDL) are involved in the removal of oxLDL. Lipoprotein apheresis (LA), which removes lipoproteins using extra-corporeal processes, is an established means of reducing Lp(a), and thereby reduces cardiovascular events. The aim of this study was to investigate the effect of LA on oxLDL and anti-oxLDL levels amongst those with refractory angina in the context of raised Lp(a). Methods: We performed a sub-study within a randomised controlled crossover trial involving 20 patients with refractory angina and raised Lp(a) > 500 mg/L, comparing the effect of three months of blinded weekly LA or sham, followed by crossover to the opposite study arm. We utilized enzyme-linked immunosorbent assays (ELISA) to quantify oxLDL and IgG/ IgM anti-oxLDL antibody levels at baseline and following three months of active LA or sham sessions. Results: Following three months of LA, there was a 30% reduction in oxLDL from 0.37 ± 0.06 to 0.26 ± 0.04 with a mean drop of −0.11 units (U) (95% CI −0.13, −0.09) compared to no significant change with sham therapy (p < 0.0001 between treatment arms). LA also led to a 22% reduction in levels of IgG and IgM anti-oxLDL, again with no significant change demonstrated during sham (p = 0.0036 and p = 0.012, respectively, between treatment arms). Conclusion: Amongst patients with refractory angina in the context of elevated Lp(a), LA significantly lowers levels of oxLDL and anti-oxLDL antibodies, representing potential mechanisms by which LA yields symptomatic and
AU  - Khan,TZ
AU  - Haskard,D
AU  - Hartley,A
AU  - Caga-Annan,M
AU  - Pennell,DJ
AU  - Collins,P
AU  - Barbir,M
AU  - Khamis,R
DO  - 10.3390/antiox10010132
PY  - 2021///
SN  - 2076-3921
TI  - Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a)
T2  - Antioxidants
UR  - http://dx.doi.org/10.3390/antiox10010132
UR  - http://hdl.handle.net/10044/1/86861
VL  - 10
ER  -
Download